Notable Labs stock under pressure as volasertib outlook dims - JMP

On Friday, JMP Securities adjusted its rating for Notable Labs, Inc. (NASDAQ:NTBL) stock, moving from Market Outperform to Market Perform. The decision came as the company undergoes a restructuring process, and there is uncertainty surrounding the future of its leading asset, volasertib.

The drug has previously demonstrated effectiveness in patients with Acute Myeloid Leukemia (AML) under Boehringer Ingelheim's management.

The firm noted that Notable Labs might have a prospective path forward if it can prove the efficacy of its Predictive Precision Medicines Platform (PPMP) in selecting patients successfully. However, due to the current business transition and the unclear prospects for volasertib, the firm sees the stock as fairly valued at the present price of $0.48.

This valuation is based on a discounted cash flow (DCF) model, which now factors in a reduced probability of success (PoS) for volasertib, down to 10% from the previous 30%.

Notable Labs reported a cash balance of $4.1 million at the end of the second quarter. The firm estimates that the current balance is approximately $2 million, equating to around $0.20 per share. This financial update provides a snapshot of the company's capital resources during a period of strategic change.

The analyst's commentary reflects a cautious stance as Notable Labs navigates through its restructuring phase. The reassessment of the stock's rating suggests a neutral outlook, with the firm waiting for further developments before reassessing the company's performance potential.

In other recent news, Notable Labs has undergone significant changes, including a strategic shift in operations and changes in leadership. The company announced a substantial reduction in its workforce and the suspension of a key Phase 2 clinical study.

The changes, approved by the Board of Directors, aim to enhance shareholder value. Notable Labs also anticipates charges of around $0.1 million, primarily related to termination benefits.

In leadership changes, Kaile A. Zagger was appointed as the Interim Chief Executive Officer and Chief Restructuring Officer. Zagger's appointment comes as Notable Labs aims to navigate through a period of transformation. Concurrently, Dr. Joseph Wagner stepped down from the interim CEO position but will continue his work as the company's Chief Scientific Officer.

On the clinical front, Notable Labs received FDA clearance to proceed with a Phase 2 clinical trial of volasertib for patients with relapsed refractory acute myeloid leukemia (R/R AML).

The trial aims to address the needs of patients who have not responded to first-line treatments. The company plans to selectively enroll patients predicted to respond to treatment, using its Predictive Medicine Platform.

Initial data from the dose optimization phase is expected by the fourth quarter of 2024, with efficacy results expected in the first half of 2025. These are recent developments that investors should note.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.